Full Press Release Details
Contact Ultragenyx Pharmaceutical Inc.
Ultragenyx Reports Second
Quarter 2016 Financial Results and Corporate Update
NOVATO, CA August 8, 2016 Ultragenyx Pharmaceutical Inc. (NASDAQ:
RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today reported its financial results and corporate update for the quarter ended June 30, 2016.
We are advancing and building our pipeline, with recent positive data from our Phase 3 study of rhGUS in MPS 7, completion of enrollment in two Phase 3
programs including KRN23 in adult X-linked hypophosphatemia and Ace-ER in GNE myopathy, and entry into a broad partnership with Takeda that provides a source of new product candidates to treat rare genetic diseases, said Emil D. Kakkis, M.D.,
Ph.D., Chief Executive Officer and President of Ultragenyx. We expect continued clinical and regulatory progress, with key milestones across each of our programs anticipated in the next twelve months.
Second Quarter 2016 Financial Results
quarter of 2016, Ultragenyx reported a net loss of $56.9 million, or $1.46 per share, basic and diluted, compared with a net loss for the second quarter of 2015 of $29.8 million, or $0.83 per share, basic and diluted. For the six months ended
June 30, 2016, net loss was $109.7 million, or $2.81 per share, basic and diluted, compared with a net loss for the same period in 2015 of $51.2 million, or $1.46 per share, basic and diluted. This reflected cash used in operations of $84.6
million for the six months ended June 30, 2016 compared to $34.9 million for the same period in 2015.
Total operating expenses for the second
quarter of 2016 were $58.1 million compared with $30.1 million for the same period in 2015, including non-cash stock-based compensation of $10.9 million and $5.1 million in the second quarter of 2016 and 2015, respectively. Total operating expenses
for the six months ended June 30, 2016 were $111.7 million compared with $51.6 million for the same period in 2015, including non-cash stock-based compensation of $21.1 million and $7.5 million in the first half of 2016 and 2015, respectively.
The increase in total operating expenses is due to the increase in development, commercial, and general and administrative costs as the company grows and advances its pipeline.
Cash, cash equivalents, and investments were $441.8 million as of June 30, 2016.
KRN23 anti-FGF23 Monoclonal Antibody in X-Linked Hypophosphatemia (XLH) and Tumor-Induced Osteomalacia (TIO)
rhGUS in Mucopolysaccharidosis 7 (MPS 7)
Ace-ER in GNE Myopathy
KRN23 in XLH and TIO
UX007 in Long-Chain Fatty Acid Oxidation Disorders
(LC-FAOD) and Glut1 Deficiency Syndrome (Glut1 DS)
Aceneuramic Acid Extended Release (Ace-ER) in GNE Myopathy
Conference Call & Webcast Information
Ultragenyx will host a conference call today, Monday, August 8, 2016 at 5pm ET to discuss second quarter 2016 financial results and to provide a corporate
update. The live and replayed webcast of the call will be available through the company s website at http://ir.ultragenyx.com/events.cfm. To participate in the live call by phone, dial 855-797-6910 (USA) or 262-912-6260 (international)
and enter the passcode 55432770. The replay of the call will be available for one year.
Ultragenyx is a clinical-stage biopharmaceutical company committed to bringing to market novel products for the treatment of rare and ultra-rare diseases, with
a focus on serious, debilitating genetic diseases. Founded in 2010, the company has rapidly built a diverse portfolio of product candidates with the potential to address diseases for which the unmet medical need is high, the biology for treatment is
clear, and for which there are no approved therapies.
Ultragenyx has completed a Phase 3 study of recombinant human beta-glucuronidase (rhGUS) in
patients with mucopolysaccharidosis 7 (MPS 7), a rare lysosomal storage disease, and is currently conducting a Phase 3 study of aceneuramic acid extended-release (Ace-ER) in patients with GNE myopathy, a progressive muscle-wasting disorder; a Phase
2 clinical study for UX007 in patients with glucose transporter type-1 deficiency syndrome (Glut1 DS), a brain energy deficiency; a Phase 2 clinical study of UX007 in patients severely affected by long-chain fatty acid oxidation disorders (LC-FAOD),
a genetic disorder in which the body is unable to convert long chain fatty acids into energy; and Phase 2 and Phase 3 studies of KRN23, an antibody targeting fibroblast growth factor 23 (FGF23), in patients with X-linked hypophosphatemia (XLH) and
tumor induced osteomalacia (TIO), both rare diseases that impair bone mineralization.
The company is led by a management team experienced in the
development and commercialization of rare disease therapeutics. Ultragenyx s strategy is predicated upon time and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit the company s website at www.ultragenyx.com.
Forward-Looking Statements
Except for the historical information contained herein, the matters set forth in this press release, including statements regarding Ultragenyx s
expectations regarding the timing of release of additional data for its product candidates, plans to initiate additional studies for its product candidates and timing regarding these studies, plans regarding ongoing studies for existing programs,
its intent to file for conditional approval and its expectations regarding timing of receiving potential approval of its product candidates, are forward-looking statements within the meaning of the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. Such forward-looking statements involve substantial risks and uncertainties that could cause our clinical development programs, future results, performance or achievements to differ significantly from those
expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the clinical drug development process, such as the regulatory approval process (including with respect to the
MAA we filed seeking conditional approval from EMA with respect to Ace-ER), whether the Phase 3 results for Ace-ER will in fact confirm or mirror the results from the prior Phase 2 study, and whether the FDA and/or EMA will accept the primary
endpoint from the Phase 3 study of Ace-ER, the timing of our regulatory filings and other matters that could affect sufficiency of existing cash, cash equivalents and short-term investments to fund operations and the availability or commercial
potential of our drug candidates. Ultragenyx undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in
these forward-looking statements, as well as risks relating to the business of the company in general, see Ultragenyx s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 10, 2016, and its subsequent
periodic reports filed with the Securities and Exchange Commission.
Ultragenyx Pharmaceutical Inc.
Selected Statements of Operations Financial Data
(in thousands, except share and per share amounts)
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
| 2016 | 2015 | 2016 | 2015 | |||||||||||||
| Statements of Operations Data: | ||||||||||||||||
| Revenue | $ | 17 | $ | $ | 17 | $ | ||||||||||
| Operating expenses: | ||||||||||||||||
| Research and development | 43,332 | 23,104 | 83,747 | 40,468 | ||||||||||||
| General and administrative | 14,738 | 7,038 | 27,945 | 11,176 | ||||||||||||
| Total operating expenses | 58,070 | 30,142 | 111,692 | 51,644 | ||||||||||||
| Loss from operations | (58,053 | ) | (30,142 | ) | (111,675 | ) | (51,644 | ) | ||||||||
| Other income, net | 1,130 | 355 | 1,995 | 478 | ||||||||||||
| Net loss | $ | (56,923 | ) | $ | (29,787 | ) | $ | (109,680 | ) | $ | (51,166 | ) | ||||
| Net loss per share, basic and diluted | $ | (1.46 | ) | $ | (0.83 | ) | $ | (2.81 | ) | $ | (1.46 | ) | ||||
| Shares used in computing net loss per share, basic and diluted | 39,028,701 | 35,937,442 | 38,999,439 | 34,997,498 |
Ultragenyx Pharmaceutical Inc.
Selected Balance Sheets Financial Data
| June 30, | December 31, | |||||||
| 2016 | 2015 | |||||||
| Balance Sheet Data: | ||||||||
| Cash, cash equivalents and investments | $ | 441,824 | $ | 536,256 | ||||
| Working capital | 379,101 | 422,289 | ||||||
| Total assets | 481,951 | 559,569 | ||||||
| Total stockholders equity | 443,895 | 531,090 |